TheraRadar
← Back
Data updated: May 24, 2026

TERSERA

Specialty

TERSERA is a specialty pharmaceutical company focused on Oncology. Key products include VARUBI.

1989
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules
Novel Drugs (2017):
1 Novel Approvals 1 First-in-Class 1 Orphan Drug

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Oncology 100%
1 drugs Phase 2: 1 Phase 1: 1

Top Competitors

Companies with the most overlap in therapeutic areas and drug targets. Based on approved drugs and pipeline focus.

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

0
Phase 3
1
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • XERMELO leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling